Setting Priorities for HIV/AIDS Interventions
Show Less

Setting Priorities for HIV/AIDS Interventions

A Cost–Benefit Approach

Robert J. Brent

HIV/AIDS is much too complex a phenomenon to be understood only by reference to common sense and ethical codes. This book presents the cost–benefit analysis (CBA) framework in a well-researched and accessible manner to ensure that the most important considerations are recognized and incorporated.
Buy Book in Print
Show Summary Details
You do not have access to this content

Chapter 25: Threshold Analysis Practice: The Costs of a Possible HIV/AIDS Vaccine

Robert J. Brent


The surest way of ending HIV/AIDS is for a vaccine to exist and be widely distributed. However, as Whiteside (2008) points out, scientific advances have been slow in this area as global spending on an AIDS vaccine is less than 1 percent of research and development spending on health products. One major reason for this lack of resources for research and development for an AIDS vaccine is that there are doubts that uninfected persons in developing countries would be able to afford to pay for it when it does get created. Even if governments want to get involved and subsidize the vaccines that are invented and produced, they also need to know how much private individuals would be willing to pay for them, as the government can then ascertain how much of a subsidy would be required to fill the gap between what people can afford and what the vaccine costs. The WTP for a vaccine can be used in the context of threshold analysis because evaluating a vaccine is a prime example of undertaking a CBA where one is missing a vital piece of information that is, in the current state of knowledge, unknowable. One cannot begin to estimate the cost of something that does not yet exist. However, one can ask what the threshold level for costs must be to ensure that the benefits that can be estimated are not exceeded. This is the question that we will attempt to answer in this chapter for one country at...

You are not authenticated to view the full text of this chapter or article.

Elgaronline requires a subscription or purchase to access the full text of books or journals. Please login through your library system or with your personal username and password on the homepage.

Non-subscribers can freely search the site, view abstracts/ extracts and download selected front matter and introductory chapters for personal use.

Your library may not have purchased all subject areas. If you are authenticated and think you should have access to this title, please contact your librarian.

Further information

or login to access all content.